Sandra R. Brave

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin et al. · Cancer Research · 2005 · 711 citations · Full text

Medicine, Oncology, Pharmacology +17

<scp>l</scp>‐N^G‐nitro arginine inhibits non‐adrenergic, non‐cholinergic relaxations of guinea‐pig isolated tracheal smooth muscle

John F. Tucker, Sandra R. Brave, Litsa Charalambous et al. · British Journal of Pharmacology · 1990 · 223 citations · Full text

Medicine, Biochemistry, Pharmacology +10

ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy

Kaye J. Williams, Brian A. Telfer, Sandra R. Brave et al. · Clinical Cancer Research · 2004 · 134 citations · Full text

Medicine, Oncology, Pharmacology +14

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

Sandra R. Brave, Kirsty Ratcliffe, Zena Wilson et al. · Molecular Cancer Therapeutics · 2011 · 88 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>

Sarah A. Loddick, Sarah J. Ross, Andrew Thomason et al. · Molecular Cancer Therapeutics · 2013 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17